Considering these promising results, we have developed MC4448, a novel highly tumor-selective HDAC3-specific inhibitor, active towards HDAC3 at submicromolar level and displaying 3 to 5 magnitude orders selectivity for HDAC3 respect to the other tested HDAC isoforms. This evidence concerns the gene HDAC9 and neoplasm.